UnknownNCT02089724

Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease

Studying Erdheim-Chester disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Groupe Hospitalier Pitie-Salpetriere
Principal Investigator
Julien Haroche, MD, PhD
Groupe Hospitalier Pitié-Salpêtrière
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20142019

Study locations (2)

Collaborators

Memorial Sloan Kettering Cancer Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02089724 on ClinicalTrials.gov

Other trials for Erdheim-Chester disease

Additional recruiting or active studies for the same condition.

See all trials for Erdheim-Chester disease

← Back to all trials